HSP
Heat shock proteins
HSP (Heat shock proteins) are a group of proteins induced by heat shock, the most prominent members of this group are a class of functionally related proteins involved in the folding and unfolding of other proteins. HSP expression is increased when cells are exposed to elevated temperatures or other stress. This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). HSPs are found in virtually all living organisms, from bacteria to humans. Heat shock proteins appear to serve a significant cardiovascular role. Hsp90, Hsp84, Hsp70, Hsp27, Hsp20 and alpha B crystallin all have been reported as having roles in the cardiovasculature.
HSP Isoform Specific Products
All Product Categories
-
HSP Inhibitors
(312)
View all products
-
HSP Agonists
(2)
View all products
-
HSP Antagonists
(6)
View all products
-
HSP Activators
(83)
View all products
-
HSP Modulators
(6)
View all products
-
HSP Inducers
(6)
View all products
-
HSP Degraders
(8)
View all products
-
HSP Pre-designed Set
(1)
View all products
-
HSP Controls
(2)
View all products
-
HSP Ligands
(8)
View all products
-
HSP Related Products (482)
Related Products (482)
-
Antibodies (46)
-
HSP Isoform Comparison
-
TCI 18
0 ImagesCat. No.: HY-185764CAS No.: 2614310-11-9TCI 18 is a ligand of HSP72 with a Ki value of 4.7 μM. TCI 18 forms a covalent bond with Lys56 residue of HSP72 via a process involving initial reversible binding, conversion to a pre-covalent complex, and subsequent covalent bond formation. TCI 18 addresses the undruggable target HSP72.
-
Diptoindonesin G
0 ImagesCat. No.: HY-125037CAS No.: 1190948-58-3Diptoindonesin G is a 2-arylbenzofuran derivative and a modulator of estrogen receptor and HSP90 middle domain. Diptoindonesin G exhibits strong cytotoxicity against mouse leukemia P-388 cells with an IC50 of 13.2 μM. Diptoindonesin G has antitumor activity and can be used in the research of tumors such as breast cancer.
-
EGFR-IN-182
0 ImagesCat. No.: HY-178955EGFR-IN-182 (Compound 4) is an EGFR inhibitor with an IC50 value of 199 nM. EGFR-IN-182 inhibits HSP90 and PI3K, with IC50 values of 5.007 and 13.596 μM respectively. EGFR-IN-182 exhibits strong anti-proliferative activity against MCF-7 and MDA-MB-231 cells. EGFR-IN-182 downregulates Cyclin D1, inducing cell cycle arrest; it enhances the activity of caspase-9, inducing cell apoptosis. EGFR-IN-182 downregulates the expressions of ERK and AKT. EGFR-IN-182 can be used for research on breast cancer.
-
JG-258
0 ImagesCat. No.: HY-148745CAS No.: 2241517-83-7JG-258 is an inactive negative control for Hsp70 inhibitors. JG-258 is an inactive structural analog of JG-98 (HY-117282), an allosteric inhibitor of heat shock protein 70 (Hsp70) with demonstrated anticancer activity. JG-258 can be used in cancer-related research.
-
Hsp90-IN-39
0 ImagesCat. No.: HY-170910CAS No.: 3065556-75-1
-
HSF1-IN-1
0 ImagesCat. No.: HY-167961CAS No.: 2205018-36-4
-
HSP90-IN-9
0 ImagesCat. No.: HY-145814CAS No.: 2765247-36-5HSP90-IN-9 is a potent and selective HSP90 inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2).
-
Hsp90β decapeptide
0 ImagesCat. No.: HY-P11185CAS No.: 1141872-74-3Hsp90β decapeptide is a C-terminal peptide of Hsp90β, which contains conserved TPR-domain MEEVD. Hsp90β decapeptide is able to bind tightly the Tah1 protein with a Kd of 1.0 μM.
-
FK 409
0 ImagesCat. No.: HY-19090CAS No.: 92454-60-9FK 409 is a NO donor that can penetrate cell membranes. FK 409 has a vasodilatory effect on bovine retinal arteries. FK 409 alleviates acute-phase inflammation, induces HSP, and mitigates liver transplantation injury in a rat model of orthotopic liver transplantation. FK 409 can be used in research on cardiovascular diseases and liver transplant rejection and inflammatory immune system disorders.
-
Antitumor agent-174
0 ImagesCat. No.: HY-161826Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity.
-
MAO A/HSP90-IN-2
0 ImagesCat. No.: HY-155580CAS No.: 2927489-99-2MAO A/HSP90-IN-2 (compound 4-C) is a dual inhibitor of HSP90and MAO A with the IC50 values of 0.016 and 4.58 μM, respectively. MAO A/HSP90-IN-2 increases HSP70 expression and reduces HER2 and phospho-Akt expression, and decreases IFN-γ induced PD-L1 expression in GL26 cells. MAO A/HSP90-IN-2 inhibits the growth of Temozolomide (HY-17364) -sensitive and -resistant GBM cells, colon cancer, leukemia, non-small cell lung and other cancers, and has potential to inhibit tumor immune escape[1].
-
TRAP1-IN-2
0 ImagesCat. No.: HY-155064CAS No.: 3031102-92-5TRAP1-IN-2 (compound 36) is a selective degrader of TRAP1 downstream proteins without affecting Hsp90's cytoplasmic downstream proteins. TRAP1-IN-2 also inhibits OXPHOS and alters cellular glycolysis metabolism. TRAP1-IN-2 destabilizes TRAP1 tetramers and disrupts mitochondrial membrane potential.
-
KU-32
0 ImagesCat. No.: HY-108248CAS No.: 956498-70-7KU-32 is a novel, novobiocin-based Hsp90 inhibitor that can protect against neuronal cell death.
-
Tanespimycin-d5
0 ImagesCat. No.: HY-10211SSynonyms: 17-AAG-d5; NSC 330507-d5; CP 127374-d5Tanespimycin-d5 (17-AAG-d5; NSC 330507-d5; CP 127374-d5) is the deuterium labeled Tanespimycin (HY-10211). Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression.
-
Hsp90-IN-41
0 ImagesCat. No.: HY-177042CAS No.: 909871-27-8Hsp90-IN-41 (Compound C1) is an inhibitor of Hsp90 (IC50 = 0.044 μM). Hsp90-IN-41 exhibits antifungal and antitumor (IC50 = 0.049 μM) activities in vitro.
-
HDAC/HSP90-IN-3
0 ImagesCat. No.: HY-144694CAS No.: 2700035-54-5HDAC/HSP90-IN-3 (compound J5) is a potent and selective fungal Hsp90 and HDAC dual inhibitor, with IC50 values of 0.83 and 0.91 μM, respectively. HDAC/HSP90-IN-3 shows antifungal activity against azole resistant C. albicans. HDAC/HSP90-IN-3 can suppress important virulence factors and down-regulate drug-resistant genes ERG11 and CDR1.
-
Chaperone complex ligand 1
0 ImagesCat. No.: HY-176951CAS No.: 3048497-50-0Chaperone complex ligand 1 is a chaperone ligand for HSP90. Chaperone complex ligand 1 can be connected to the MET ligand (HY-50878) by a linker to synthesis of MET degrader OZD-MET 01 (HY-177893).
